首页> 外文OA文献 >Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex)

【2h】

Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex)

机译：患有CHA2DS2-VASc分数的其他危险因素（非性别）的非瓣膜性心房颤动患者口服抗凝药物，阿司匹林或不进行治疗的净临床收益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lip Gregory Y.H.; Skjøth Flemming; Rasmussen Lars Hvilsted; Nielsen Peter B.; Larsen Torben Bjerregaard;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) [J] . Gregory Y.H. Lip, Flemming Skjoth, Lars Hvilsted Rasmussen, Journal of the American College of Cardiology . 2015,第4期

机译：非瓣膜性心房颤动患者口服抗凝药物，阿司匹林或不进行治疗的净临床获益，且CHA2DS2-VASc评分的其他危险因素另计（性别以外）
2. Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation? [J] . Juan WANG, Da-Peng ZHANG, Hong-Bin LIU, 老年心脏病学杂志（英文版） . 2018,第003期

机译：作为CHA2DS2-VASc评分的另一个危险因素的高血压房颤患者是否应该接受口服抗凝治疗？
3. Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Piccini Jonathan P., Stevens Susanna R., Chang YuChiao, Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：对有关“非瓣膜性房颤患者中风和全身性栓塞的预测指标：肾功能不全：ROCKET AF（Rivaroxaban每日一次，口服，直接因素）中的R（2）CHADS（2）指数的验证的答复Xa抑制与维生素K拮抗剂在房颤预防卒中和栓塞试验中的比较以及ATRIA（房颤的抗凝和危险因素）研究队列”
4. Effects of Computerized Guideline-Oriented Clinical Decision Support System on Antithrombotic Therapy in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis [C] . Ryota Sakurai, Kazuhiko Ohe MEDINFO . 2019

机译：面向计算机化指南临床决策支持系统对心房颤动患者抗血栓形成的影响：系统综述与荟萃分析
5. Early Identification and Intervention in Patients with Atrial Fibrillation Using an Implantable Cardiac Monitor to Significantly Improve Guideline-Based Anticoagulation Therapy in an Outpatient Cardiology Clinic [D] . Alvarez, Lisa 2019

机译：使用可植入式心脏监护仪对房颤患者的早期识别和干预，可显着改善门诊心脏病学诊所基于指南的抗凝治疗
6. Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation? [O] . Juan Wang, Da-Peng Zhang, Hong–Bin Liu, 2018

机译：作为CHA2DS2-VASc评分的另一个危险因素的高血压房颤患者是否应该接受口服抗凝治疗？
7. Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) [O] . Lip, Gregory Y H, Skjøth, Flemming, Rasmussen, Lars Hvilsted, 2015

机译：非瓣膜性心房颤动患者口服抗凝，阿司匹林或无治疗的净临床效益，其中1例CHa2Ds2-Vasc评分的其他危险因素（超越性别）

Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex)

著录项

引文网络

相似文献

相关主题

期刊订阅